Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Apr 9;8(7):1772-1775.
doi: 10.1182/bloodadvances.2023011426.

Impact of MYC and BCL2 double expression on outcomes in primary CNS lymphoma: a UK multicenter analysis

Edward Poynton  1   2 , Emily Chernucha  3 , James Day  2 , Catherine Prodger  4 , David Hopkins  5 , Pallav Rakesh  6 , Tess O'Neill  7 , Nisha Thakrar  2 , Ayse Akarca  8 , Esraa Jamal  1 , Ayesha Ali  9 , Amy A Kirkwood  10 , Sabine Pomplun  8 , Teresa Marafioti  8 , Maria Calaminici  1 , Paul Greaves  11 , Sridhar Chaganti  6 , Pam McKay  5 , Jeffery Smith  12 , Toby A Eyre  4 , Nicolas Martinez-Calle  3 , Kate Cwynarski  2 , Christopher P Fox  13 , Jessica Okosun  1
Affiliations
Multicenter Study

Impact of MYC and BCL2 double expression on outcomes in primary CNS lymphoma: a UK multicenter analysis

Edward Poynton et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: J.S. reports consulting or serving in an advisory role for AbbVie and AstraZeneca. T.A.E. reports consulting or serving in an advisory role for Roche, Gilead/Kite, Loxo Oncology, BeiGene, Incyte, Secura Bio, and Autolus; honoraria from Roche, Gilead/Kite, Janssen, AbbVie, and AstraZeneca; and research support from Gilead, AstraZeneca, and BeiGene. P.M. reports consulting or serving in an advisory role for Gilead/Kite, Incyte, Janssen, AbbVie, AstraZeneca, BeiGene, Celgene/Bristol Myers Squibb (BMS), Epizyme, Roche, and Takeda. S.C. reports consulting or serving in an advisory role for AbbVie, Adicet Bio, Atara Biotherapeutics, Gilead/Kite, Novartis, Orion Pharma, Pierre Fabre, Roche, and Takeda. K.C. reports consulting or serving in an advisory role for BeiGene, Roche, Celgene/BMS, Takeda, Gilead/Kite, Incyte, Atara, and Janssen. C.P.F. reports consulting or serving in an advisory role for Roche, BeiGene, Gilead/Kite, Incyte, Janssen, Roche, Takeda, AbbVie, AstraZeneca, Atara Bio, and Celgene/BMS, and research support from BeiGene. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Adverse clinical outcomes associated with double expressor status. Association of double expression of MYC (>40%) and BCL2 (>50%) with PFS and OS in the entire cohort (A-B) and in the MATRix-treated subgroup (C-D).
See this image and copyright information in PMC

References

    1. Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 2011;105(9):1414–1418. - PMC - PubMed
    1. Martinez-Calle N, Poynton E, Alchawaf A, et al. Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival. Br J Haematol. 2020;190(3):394–404. - PubMed
    1. Ahn Y, Ahn HJ, Yoon DH, et al. Primary central nervous system lymphoma: a new prognostic model for patients with diffuse large B-cell histology. Blood Res. 2017;52(4):285–292. - PMC - PubMed
    1. Ferreri AJM, Cwynarski K, Pulczynski E, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3(5):e217–227. - PubMed
    1. Ferreri AJM, Cwynarski K, Pulczynski E, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017;4(11):e510–e523. - PubMed

Publication types

MeSH terms

Substances